The layoffs will affect 150 long-tenured salespeople in Gilead’s cardiopulmonary division, which markets two drugs, Ranexa and Letairis, which recently lost patent exclusivity.
The decision is unfortunate but necessary to cut costs, Gilead said. The drugmaker already warned investors that sales generated by the two drugs would fall as generics enter the market.
The layoffs are effective July 1.
More articles on pharmacy:
PBM hearing should prompt bill to ban ‘secrecy’ in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy
